CRL · 10-Q · 2026Q3 · Full report
Market Demand Trends
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-04 · Importance 49 · Surprise 32 · In source text
Charles River reported an improving client spending environment, principally in Discovery and Safety Assessment (DSA), as biotech funding increased and global biopharmaceutical companies refocused investment on early-stage R&D pipelines. DSA backlog increased slightly to $2.0 billion at September 26, 2026, from $1.9 billion at December 27, 2025. In the third quarter, regulated safety assessment services revenue increased $33.5 million year over year, partially offsetting the impact of the European Discovery Services divestiture.
Key facts
- DSA backlog increased slightly to $2.0 billion as of September 26, 2026, from $1.9 billion as of December 27, 2025. source
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported improved client spending conditions, principally in DSA, driven primarily by increased biotech funding and global biopharmaceutical companies refocusing investment on early-stage R&D pipelines. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | DSA backlog increased slightly to $2.0 billion as of September 26, 2026, from $1.9 billion as of December 27, 2025. |